Forbes dedicated a fascinating article about Takis and our race to develop a vaccine against the new Coronavirus Sars-Cov-2.

Covid-19 is an opportunity for us to learn: this is the first disease we have worked with and tried to find a solution for. Our DNA-electroporation technology is very versatile and it can be adapted for a virus that mutates, like Sars-Cov-2, but also for new diseases that emerge from other species.

We are convinced that Takis will emerge stronger and better prepared to fight future outbreaks.

Read the full article on Forbes: